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p73 is required for appropriate BMP-induced
mesenchymal-to-epithelial transition during somatic
cell reprogramming
Marta Martin-Lopez1, Laura Maeso-Alonso1, Sandra Fuertes-Alvarez1, Diego Balboa2, Virginia Rodríguez-Cortez3, Jere Weltner2,
Inmaculada Diez-Prieto1,4, Andrew Davis5, Yaning Wu5, Timo Otonkoski2, Elsa R Flores5, Pablo Menéndez3,6,7, Margarita M Marques8
and Maria C Marin*,1
The generation of induced pluripotent stem cells (iPSCs) by somatic cell reprogramming holds great potential for modeling human
diseases. However, the reprogramming process remains very inefficient and a better understanding of its basic biology is required.
The mesenchymal-to-epithelial transition (MET) has been recognized as a crucial step for the successful reprogramming of
fibroblasts into iPSCs. It has been reported that the p53 tumor suppressor gene acts as a barrier of this process, while its homolog
p63 acts as an enabling factor. In this regard, the information concerning the role of the third homolog, p73, during cell
reprogramming is limited. Here, we derive total Trp73 knockout mouse embryonic fibroblasts, with or without Trp53, and examine
their reprogramming capacity. We show that p73 is required for effective reprogramming by the Yamanaka factors, even in the
absence of p53. Lack of p73 affects the early stages of reprogramming, impairing the MET and resulting in altered maturation and
stabilization phases. Accordingly, the obtained p73-deficient iPSCs have a defective epithelial phenotype and alterations in the
expression of pluripotency markers. We demonstrate that p73 deficiency impairs the MET, at least in part, by hindering BMP
pathway activation. We report that p73 is a positive modulator of the BMP circuit, enhancing its activation by DNp73 repression of
the Smad6 promoter. Collectively, these findings provide mechanistic insight into the MET process, proposing p73 as an enhancer
of MET during cellular reprogramming.
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Embryonic stem cells (ESCs) are defined by their ability to
proliferate by symmetrical cell divisions and to give raise to all
specialized cell types (pluripotency).1 The possibility of
generating induced pluripotent stem cells (iPSCs), with similar
ESC-stemness, by the overexpression of the transcription
factorsOct4, Sox2, Klf4 and c-Myc (OSKM),2 has created new
opportunities for developmental biology, disease modeling
and regenerative medicine.3–5
iPSCs generation from mouse embryonic fibroblasts
(MEFs) is a slow and inefficient process in which fibroblasts
gradually lose their mesenchymal identity and assume an
embryonic gene expression pattern. Functional genomics
studies have defined three phases during fibroblast
OSKM-induced reprogramming (termed initiation, maturation
and stabilization), and uncovered an early mesenchymal-to-
epithelial transition (MET) that marks the initiation phase,6,7
which is dependent upon intrinsic BMP signaling. Indeed,
BMP-SMAD signaling activation promotes iPSCs generation
in the early reprogramming phase, confirming its role in the
induction and maintenance of pluripotency.8
The MET process, a rate-limiting step during reprogram-
ming, is tightly linked with the epithelial phenotype and the
pluripotent state of iPSCs.6,9 MET, as well as its reversal
epithelial-to-mesenchymal transition (EMT), has roles in
developmental biology and metastasis, highlighting the fact
that reprogramming and tumor progression share some
similarities.10 Consistently, reprogramming requires, like
tumor progression, that successive barriers must be over-
come to reach stemness.11 The nature of these barriers are
not completely understood, but the involvement of tumor
suppressors like p5312–15 or Rb116 as reprogramming hurdles
has been reported, launching the hypothesis that tumor
suppression mechanisms must be acting as blockades of
cellular reprogramming, maintaining the differentiated state
and genomic stability.
Members of the p53 family, comprised by the transcription
factors p53, p63 and p73, share many functional properties,
but also perform unique, and some time antagonist, biological
functions.17 Inhibition of the p53 pathway increases iPSCs
generation efficiency,12–15,18 whereas p63 has been reported
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to act as an enabling factor.19 A variety of p53-induced
protective pathways impair reprogramming including, but not
limited to, those involved in the regulation of cell growth, mainly
by p53-downstream targets p21Cip1 or miR-34.12,20 In addition,
the p53–p21 axis can also restrain reprogramming by the
inhibition of the MET.21 However, reports regarding p73 role in
cellular reprogramming are inconclusive.19,22 DNp73 over-
expression was reported to increase human iPSCs generation
efficiency,22 while other report concluded that p73 had no role
in reprogramming, proposing that the DNp73 effect was due to
its p53-dominant-negative effect.19 Here, we demonstrate that
p73 deficiency impairs MEFs reprogramming efficiency by
abating BMP-induced MET, even in the absence of p53. In
agreement, p73-deficient iPSCs have an attenuated epithelial
phenotype and alterations in pluripotency markers expres-
sion. We report, for the first time, that p73 is part of the BMP
circuit, enhancing BMP signaling, at least in part, by DNp73
transcriptional repression of the Smad6 promoter.
Results
p73 is required for effective reprogramming by OSKM
and OSK, independent of p53. To analyze the effect of total
p73 deficiency on reprogramming, particularly in the context
of p53-loss, we sought to compare the reprogramming
efficiencies of WT, p73KO, p53KO and double mutants
DKO-MEFs. We transfected early passage MEFs (P4) with
piggyBac transposon vectors encoding OSKM regulated by a
doxycycline (Dox)-inducible system.23 Reprogramming was
monitored according to previously defined morphological
criteria (emergence of small cells forming compact round
colonies with well-defined borders), as well as alkaline
phosphatase (AP) activity.24,25 After two weeks, small
colonies began to appear in WT and p73KO cultures, and
colonies with ESC-like morphology were collected at day 22.
While WT cultures displayed typical ESC-colonies at this
point, p73KO cultures exhibited a significantly lower number
of irregular AP+ colonies (Figure 1a), indicating that lack of
p73 blunted the reprogramming efficiency. Next, we
addressed whether p53-induced reprogramming barriers
could be accountable for the observed effect. Thus, we
analyzed the expression level of p21CIP1 and miR-34a.12,20
Lack of p73 neither augmented the basal expression levels of
these two p53-targets in MEFs, nor its induction after 7 days
of Dox-treatment (Supplementary Figure 1a).
Trp53− /− significantly accelerated MEFs reprogramming
kinetics; however, Trp73− /− attenuated this p53KO-
enhancing effect (Figure 1b). Lack of c-MYC delayed and
attenuated WT-MEFs reprogramming26 and in this setting,
p73KO cultures were severely affected (Figure 1c). p53
deficiency boosted OSK-reprogramming efficiency
(Figure 1d), but lack of p73 also decreased p53KO-
enhancing effect in these conditions (Figure 1d).
To rule out the possibility that the observed effect was due to
different MEFs proliferative indexes,27 we analyzed growth
curves from early passage MEFs littermates and found, at this
early passages, no significant differences between either WT
and p73KO, nor p53KO and DKO growth kinetics
(Supplementary Figure 1b).
p73 deficiency impairs MET resulting in an altered
maturation and stabilization phases. Both Trp73 isoforms,
TA- and DNp73, were upregulated during reprogramming,
being DNp73 significantly induced during the early stages of
the process (Figure 2b). We used an alternative model to
confirm p73 isoforms upregulation: reprogrammable-MEFs
(Rep-MEFs)28 displayed primary mouse-ES colony-like
structures 5 days after Dox-treatment and, by day 9, colonies
were AP+ (Supplementary Figures 2a,b). qRT-PCR analysis
confirmed DNp73 as the predominant isoform induced during
Rep-MEFs reprogramming (Supplementary Figure 2c).
To substantiate specific p73-isoform requirement for
reprogramming, we attempt to reprogram TAp73 and
DNp73-specific knockout MEFs.29 We carry out the repro-
gramming experiments (Supplementary Figure 3a) and 5 days
upon Sendai Virus transfection, the first mouse-ES colony-like
structures began to be detected in WTand, to a lesser extent,
in the TAp73-deficient MEFs (Supplementary Figures 3b,c).
After 21 days, WT colonies progressed and were efficiently
reprogrammed, becoming AP+ and expressing the pluripo-
tency marker SSEA-1 (Supplementary Figures 3d,e). How-
ever, neither TAp73− /− , nor DNp73− /− , colonies
progressed to a reprogrammed state by the end of the
experiment (Supplementary Figure 3d), indicating that while
DNp73 appears to be the predominantly expressed isoform,
both isoforms appear to be required for the complete
reprogramming.
To identify the phase of reprogramming affected by p73
deficiency, we characterized the expression kinetics of
initiation, maturation and stabilization phasemarkers,6 collect-
ing RNA samples at 7, 12 and 17 days after Dox-treatment
(Figure 2a). The initiation phase (Figure 2b) is defined by the
induction of epithelial-associated genes with a concomitant
decrease of mesenchymal genes.9 Therefore, we examined
the expression of epithelial markers like E-cadherin (which is
upregulated during METand crucial for reprogramming21) and
Epcam.We found that in p73KO cultures upregulation ofCdh1
or Epcam was significantly reduced, while the mesenchymal
associated gene Snail showed a significant increase in the
absence of p73 (Figure 2c), suggesting p73 requirement for
appropriate METestablishment.
Dysregulation of MET genes impairs MEF reprogramming,7
thus, we speculated that in p73-deficient cells the maturation
and stabilization stages would be altered. Nanog expression
begins to increase duringmaturation phase30,31 (Figure 2c). In
agreement with an altered maturation, p73KO-iPSCs dis-
played attenuated Nanog expression and delayed kinetics
profile (Figure 2d), as well as highly reduced levels of Lin28, a
gene required for iPSCs maturation32 (Figure 2c). Moreover,
expression of Pecam1 was significantly decreased at the end
of the stabilization phase in p73KO cells (Figure 2c),
altogether demonstrating that lack of p73 impairs MET and
alters the subsequent phases of the process resulting in a
defective and inefficient reprogramming process.
Trp53 also blocks somatic cell reprogramming by inhibiting
MET through mechanisms independent of the proliferation or
apoptosis pathways;21 thus, we sought to investigate whether
p53 deficiency could counteract p73 requirement for MET
induction. p53 deficiency resulted in a strongCdh1 andEpcam
induction21 (Figure 3). Lack of p73 significantly reduced this
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induction despite p53 absence, highlighting p73 importance
for the epithelial phenotype. However, Trp73 loss did not affect
the suppression of mesenchymal markers in this context
(Figure 3), confirming that mesenchymal and epithelial
transcriptional regulators are controlled by independent
pathways,9 and that p73 regulates primarily the epithelial
profile. It is noteworthy that lack of p73 had a stronger
repressive effect in the induction of Nanog, Lin28 and Pecam1
expression, which levels are close to WT values in the DKO
cells (Figure 3), altogether suggesting that these cells might
not be attaining a fully reprogrammed state.
p73 is dispensable for iPSC self-renewal but required for
a complete reprogrammed state. We obtained iPSCs lines
by selecting primary-colonies with ESC-like morphology and
expanding them by successive passages in the absence of
Dox. We had severe difficulties establishing p73-deficient
colonies, since many of them detached from the culture
surface and did not survive after the second passage. We had
only a 60%±7.14 (p73KO) and 50%±8.47 (DKO) success
rate of colony establishment, compared with 90%±3.47 and
80%±3.41 for the WT- and p53KO-colonies, respectively.
Nevertheless, the established colonies were grown and
maintained in culture for more than 20 passages, indicating
that p73 was not necessary to maintain self-renewal once the
iPSC line was established (Figure 4a).
WT- and p53KO-iPSCs lines expressed key molecular
markers for pluripotency, like Nanog, SSEA-1 (Figure 4b) or
Lin28 (Figure 4c). However, p73KO-iPSCs showed slightly
lower levels of Nanog and SSEA-1 (Figure 4b). Lin28 analysis
revealed that p73-deficient cells did not achieve appropriate
expression levels (Figure 4c), supporting the idea that these
cells might not have attained full pluripotency. Nevertheless,
when cultured under differentiating conditions,33 all derived
lines showed efficient embryoid body formation and positive
staining for lineage markers of the three germ layers
(Figure 4c).
Colonymorphology is one of the criteria to identify bona-fide
ESC. In this regard, WT- and p53-iPSC colonies had the
expected refractive appearance with tight and well-defined
borders. However, p73KO-iPSC colonies, and DKO, were less
compact, and had polygonal morphology and diffuse borders
(Figure 5a). Moreover, at late passage, some of the DKO-iPSC
lines lost mESC-colony morphology (Figure 5b), suggesting
that they were not stable. In agreement, p73-deficient iPSCs
had reduced levels of E-Cadherin (Figure 5c), crucial for
colony compaction and full pluripotency maintenance.34
Orthogonal projections of confocal microscopy images con-
firmed that WT-iPSC colonies were dome-shaped, with
WT p73KO p53KO DKO
WT p73KO p53KO DKO
Figure 1 Trp73 deficiency impairs reprogramming efficiency, even in the absence of p53. MEFs of the indicated genotypes, cultured and treated identically, were transfected
with OSKM (a and b) or OSK factors (c and d) and the reprogramming efficiency was monitored by quantification of alkaline phosphatase positive colonies (AP+) after either
22 days for WTand p73KO (a and b) or 17 days for p53KO and DKO (c and d) of doxycycline treatment. Representative scanned plates and photomicrographs (10 × ) of the
colonies are shown for each condition. Two independent reprogramming experiments were performed, including at least three biological replicates from the indicated genotypes
(with the exception of p53KO-MEFs, n= 2), with two independent transfections per replicate. Mean± S.E.M. are represented, equal variance. Student's t-test was performed to
evaluate statistical differences; *Po0.05, **Po0.01, ***Po0.001
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several layers of cells (Figure 5d, dotted arrows) in which
E-Cadherin was sharply localized at the plasma membrane
(white arrows). To the contrary, p73KO-colonies were almost
flat (1-2 cell layers) and had lower and diffuse expression of
E-Cadherin. Reports have shown that β-catenin localization is
a determinant factor of the pluripotent capacity.35 In accor-
dance, β-catenin colocalized with E-Cadherin at the plasma
membrane in the WT cells from the colony center that were
establishing tight cell–cell interactions (Figure 5d, white
arrows), but not in cells at the edge of the colony (arrowheads)
which are prone to differentiate.35 p73KO cells had a diffuse
distribution of E-Cadherin through the plasma membrane and
displayed abundant cytoplasmic β-catenin (short arrows),
indicating that E-Cadherin/β-catenin interactions were lost in
many p73KO cells (yellow arrows). mRNA expression analysis
of Cdh1 and Epcam confirmed significantly reduced levels of
these epithelial genes in p73-deficient cells (Figure 5e),
altogether indicating that lack of p73 resulted in an impaired
epithelial phenotype. Thus, our data suggest that p73
deficiency leads to defects on MET establishment during the
initiation phase of OSKM-induced reprogramming, which not
only result in decreased reprogramming efficiency, but also
lead to alterations in the establishment of cell junctions
involving E-cadherin.
p73 is a positive modulator of the BMP circuit required
for the OSKM-induced BMP signaling during the initia-
tion phase of reprogramming. Next, we sought to identify
the mechanism underlying p73 requirement for MET estab-
lishment. MET induction is dependent upon the intrinsic
activation of BMP cascade.6 We investigated if p73 deficiency
affected OSKM-activation of BMP signaling by measuring Id1
expression, the immediate early BMP response gene.36 As
expected, WT cells underwent a 2.4-fold increase in Id1
expression after 7 days of Dox-treatment, but no Id1 induction
was detected in p73KO cells (Figure 6a), suggesting a role of
p73 as a BMP signaling modulator. BMP signal is fine-tuned
by feedback mechanisms orchestrated, among others, by the
intracellular Smad inhibitor, Smad6.37 We observed a
significant induction of Smad6 expression in p73KO cells
when compared with WT cells (Figure 6b, left panel).
Accordingly, higher levels of Smad6 were detected in
p73KO-MEFs (Figure 6b, right panel). Moreover, BMP







Figure 2 Lack of p73 impairs METresulting in altered maturation and stabilization phases. (a) Overview of the experimental design of MEFs reprogramming by doxycycline
inducible OSKM transfection and sample collection during the initiation, maturation and stabilization phases of the process. (b and c) Analysis of the expression kinetics profile of
markers during the reprogramming process of WT (b and c) and p73KO (c) MEFs. RNA samples were collected at the indicated days and expression analysis was performed by
qRT-PCR: (b) TA and DNp73; (c) Cdh1, Snail, Nanog, Epcam, Lin28 and Pecam1. Expression of the indicated genes was normalized to 18S and set to 1 for non-transfected MEFs
in each graph (t= 0). Analysis was performed with data from two independent experiments, with at least three biological replicates from the indicated genotypes, with two
replicates per sample. Mean±S.E.M. are represented, equal variance. Student's t-test was performed to evaluate statistical differences. *Po0.05, **Po0.01, ***Po0.001
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levels of phosphorylated-Smad1/5/8, was remarkably
reduced in the obtained p73KO-iPSC clones (Figure 6c).
We evaluated p73 expression after BMP4 treatment of
serum-deprived embryonal carcinoma P19 cells, known to
upregulate Smad6 in response to BMPs.37 As depicted in
Figure 6d, BMP-induced DNp73 levels, but not TAp73,
correlated with increased levels of other BMP targets like Id1
or Smad6. Moreover, ectopic expression of DNp73 in serum-
deprived P19 cells, enhanced BMP4-induced Id1 expression
(Figure 6e, left panel) and prolonged Smad1/5/8 phosphoryla-
tion (Figure 6e, right panel). DNp73 role as an enhancer of
BMP signaling was also investigated in the Tet-OFF inducible
cell line H1299-DNp73.38 In this system, reported to secrete
low levels of endogenous BMP4,39 cells cultured in the
presence of serum, but without BMP4 treatment, displayed
detectable levels of p-Smad-1/5/8 that were enhanced upon
induction of DNp73 expression (Figure 6f). Moreover, in
serum-deprived conditions, DNp73 expression enhanced
BMP4-induced Smad1/5/8 activation (Figure 6g), demonstrat-
ing that DNp73 expression potentiated BMP signaling
cascade.
DNp73 directly binds the SMAD6 promoter and represses
its BMP-induced activation. DNp73 capacity to lengthen
BMP cascade activation, together with the higher levels of
Smad6 detected in p73KO-MEFs, lead us to hypothesize that
DNp73 might be a direct repressor of this BMP inhibitor,
modulating in this way, the BMP-negative feedback loop.
Supporting this idea, overexpression of DNp73, but not
TAp73, significantly reduced BMP4-induced Smad6 mRNA
levels (Figure 7a), suggesting that Smad6 could be a DNp73
transcriptional target.
Thus, to address whether SMAD6 was transcriptionally
regulated by DNp73, we performed an in silico prediction of
p53-responsive elements within the human SMAD6 gene
using p53Family-Target-Genes data base.40 This analysis
unveiled a p53-binding site located between nt − 2769 to
− 2737 from the transcription start site (position +1), that was
partially conserved in the murine Smad6 promoter
(Supplementary Figure 4a). We analyzed DNp73 ability to
antagonize BMP4-induced activation of the Smad6 promoter
using a Smad6-Luc reporter37 in P19 cells. DNp73, but not
TAp73, significantly repressed BMP4 activation of the reporter
gene (Figure 7b). As TA- and DNp73 can antagonistically
regulate certain genes, we investigated whether DNp73 could
repress BMP4-induced Smad6 promoter activation, in the
presence of TAp73. DNp73 was capable of significantly block
BMP4-induced transcriptional activation independently of
TAp73 expression (Figure 7c). Thus, physiological upregula-
tion of TAp73 during the process was not opposing DNp73
modulation of BMP cascade.
Next, we performed chromatin immunoprecipitation (ChIP)
assays in H1299 cells, in 10% serum conditions to
demonstrate that endogenous DNp73 could directly bind to
the SMAD6 promoter p53-RE. Cross-linked cellular extracts
were immunoprecipitated and the interacting DNA was
quantified by qPCR using primers specific for the p53-REs












Figure 3 p53 deficiency could not fully counteract p73 requirement during reprogramming. Expression kinetics analysis of METand pluripotency markers during the p53KO
and DKO-MEFs reprogramming process. RNA samples were collected at the indicated days and expression analysis was performed by qRT-PCR: Cdh1, Snail, Nanog, Epcam,
Lin28 and Pecam1. Expression of the indicated genes was normalized to 18S and set to 1 for non-transfected MEFs in each graph (t= 0). Analysis was performed with data from
two independent experiments, with at least three biological replicates from the indicated genotypes (two biological replicates in the case of p53KO cells), with two replicates per
sample. Mean±S.E.M. are represented, equal variance. Student's t-test was performed to evaluate statistical differences; *Po0.05, **Po0.01, ***Po0.001
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IgG-pulldown as background. As expected, p21CIP1 showed
a 13.7± 5.38-fold enrichment compared to IgG (P= 0.024;
Figure 7d, left panel). More importantly, we observed a
significant in vitro direct interaction of DNp73 with theSMAD6
promoter p53-RE (6.80± 1.73; P= 0.004; Figure 7d, right
panel), demonstrating that this gene is a direct DNp73
transcriptional target. This enrichment was not detected








































WT p73KO p53KO DKO
WT p73KO p53KO DKO
Figure 4 p73 is dispensable for iPSCs self-renewal and in vitro pluripotency, but p73-deficient cells have decreased pluripotency marker expression and might not have
attained full stemness. Three clones for each genotype were analyzed. All the p73-defective clones displayed the altered phenotype (a–c) iPSCs of the indicated genotype were
cultured under proliferating and non-differentiating conditions and analyzed. (a) Representative phase contrast images (Objective 5 × ; Scale: 250 μm) of iPSCs cultures
corresponding to the 20th passage. (b) Confocal microscopy analysis of pluripotency markers Nanog (red) and SSEA-1 (green). DAPI was used to visualize nuclei. Objective
20 × . Scale: 80 μm. (c) Quantification of Lin28 expression by qRT-PCR. Mean values± S.E.M. from duplicates of at least three clones per genotype from two independent
experiments are shown, equal variance. Expression was analyzed by qRT-PCR, normalized to 18S. Student's t-test was performed to evaluate statistical differences *Po0.05,
**Po0.01, ***Po0.001. (d) iPSCs lines of the indicated genotype were differentiated by embryoid body (EB) formation under differentiating conditions and lineage markers of
three germ layers were analyzed: Tuj-1 (ectoderm, green), CD31 (mesoderm, red) and AFP (endoderm, red). At least three clones per genotype were analyzed. DAPI was used to
visualize nuclei. Objective 20 × . Scale: 80 μm
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Figure 5 Lack of p73 results in altered iPSC colony morphology and attenuated epithelial phenotype. (a–e) iPSCs of the indicated genotype were cultured under proliferating and
non-differentiating conditions and analyzed. (a and b) Representative phase contrast images of iPSCs cultures corresponding to late passages (Objective 20 × in a and 10 × in b; Scale:
250 μm). Three clones for each genotype were analyzed. All the p73-defective clones displayed the altered phenotype. (c) Confocal microscopy analysis of E-cadherin immunostaining
(red) (Objective 20 × ; Scale: 80 μm). (d) Orthogonal projections of three-dimensional reconstruction images of iPSCs immunostained with β-catenin (red) and E-cadherin (green)
antibodies. The lateral views are indicated by the dotted arrows and indicate the layers of cells that compose the colony. Co-localization of β-catenin and E-Cadherin at the plasma
membrane in tight cell–cell interactions is indicated by white arrows, and cell with no co-localization at the plasma membrane are marked with arrowheads. In p73KO cells with diffuse
distribution of E-Cadherin and cytoplasmic β-catenin are marked by arrowheads and cell without E-Cadherin/β-catenin interactions by yellow arrows. Objective 63 × . Scale: 20 μm. (e)
Quantification ofCdh1 and Epcam expression by qRT-PCR. Mean values±S.E.M. from duplicates of at least three clones per genotype (two biological replicates in the case of p53KO)
from two independent experiments are shown, equal variance. Student's t-test was performed to evaluate statistical differences *Po0.05, **Po0.01, ***Po0.001
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identified SMAD6 p53-RE but with no p53-RE homology
(1700 bp downstream of the p53-RE, Supplementary
Figure 4a). ChIP analysis with anti-DNp73 antibody in WT-
and p73-deficient iPSCs revealed a 16.28± 4.14-fold enrich-
ment compared to IgG (P= 0.00244; Figure 7d, lower panel)
in WT-iPSCs but not in p73KO-iPSCs, further demonstrating
the specificity of DNp73 direct interaction with the Smad6
promoter.
Discussion
Somatic cell reprogramming is an inefficient process in which
successive barriers must be overcome to reach the pluripotent
state.27,42 It is well established that tumor suppressor genes
such as p53, p16INK or Rb1, that control cell proliferation,
differentiation and cell death, serve as key regulators limiting
cell reprogramming and maintaining cell fate and genomic
stability.43 The members of the p53 family are transcription
factors known to regulate such processes in somatic and stem
cells.17 The emerging picture portraits an interconnected
network in which p63 and p73 share many p53-functional
properties, but also perform unique, and some time antago-
nist, biological functions.44,45 Along the same line, p53 and
p63 seem to play opposites roles in MEFs reprogramming.
Trp53 abatement enhances and accelerates reprogramming
yielding defective iPSCs with genomic instability and in vivo
tumorigenic potential,21 while Trp63, DNp63 in particular, has
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Figure 6 p73 is a positive modulator of the BMP circuit required for the OSKM-induced BMP signaling during the initiation phase of reprogramming. (a and b) Analysis of the
expression kinetics profile of markers during reprogramming process of WTand p73KO-MEFs. RNA samples were collected at the indicated days and expression analysis was
performed by qRT-PCR: (a) Id1 (b) Smad6 (left panel). Expression of the indicated genes was normalized to 18S and set to 1 for non-transfected MEFs in each graph (t= 0). (b)
Quantification of Smad6 expression by qRT-PCR in MEFs (right panel). Expression was normalized to 18S. Analysis was performed with data from two independent experiments,
with at least three biological replicates from the indicated genotypes, with two replicates per sample. Mean±S.E.M. are represented, equal variance. Student's t-test was
performed to evaluate statistical differences. *Po0.05, **Po0.01, ***Po0.001. (c) Western blot analysis of BMP signaling cascade activation in WTand p73KO-iPSC clones.
(d) Quantification of Id1, Smad6, TAp73 and DNp73 expression by qRT-PCR after BMP4 treatment (0–50 ng/ml BMP4) in serum-deprived P19 cells. (e–g) P19 cells were
transfected with DNp73 expression plasmid and after 18 h, cells were serum-deprived for 24 h and then, treated with BMP4. At the indicated time points BMP cascade activation
was analyzed by quantification of Id1 by qRT-PCR (e, left panel) or phospho-Smad1/5/8 expression by western blot assay (e, right panel). (f and g) The Tet-OFF inducible cell line
H1299-DNp73 was cultured on serum conditions (e) or serum-deprived (g) before inducing DNp73 expression in the presence or absence of BMP4 (g). BMP cascade activation
was analyzed by phospho-Smad1/5/8 expression by western blot assay. Equal amounts of total protein were loaded and β-actin serves as loading control. Note that HA (Y11)
antibody detects the exogenous DNp73 protein expression. At least two independent experiments were performed with similar results
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information concerning p73 role in the reprogramming process
is contradictory. DNp73 was reported to increase human
iPSCs generation efficiency,22 while other study concluded
that p73 has no role in MEFs reprogramming and proposed
that DNp73 effect was mediated by its p53-dominant negative
effect.19 To shed light on this issue, we reprogrammed total
Trp73 knockout MEFs, with or without Trp53, with the
Yamanaka factors. Our data demonstrate that the reduced
reprogramming efficiency of p73-deficient MEFs cannot be
explained by enhanced p53 activity, as previously proposed,19
supporting a specific p73 function during reprogramming,
independent of DNp73-dominant-negative effect over p53.
Thus, while the data presented in this work is in accordance
with DNp73 positive role during reprogramming, it is in
contradiction with the second report.19 This one indicated that
p73 deficiency had no effect on iPSC generation, self-
maintenance or pluripotency. Nevertheless, some of our
results are in partial consonance with their observations. We
demonstrate that lack of p73 decreased the reprogramming
efficiency; however, we obtained p73KO-iPSC clones and
showed that p73 is dispensable for iPSC self-renewal.
Moreover, p73KO-iPSCs could be differentiated into cells of
the three germ layers, including neural progenitor cells, but a
close analysis of p73KO-iPSCs revealed that p73 deficiency
resulted in decreased pluripotency markers, altered morphol-
ogy and attenuated epithelial phenotype.
During OSKM-mediated reprogramming, the majority of
cells never complete the process, and only a small number
become iPSCs.11 We provide evidence that the lack of p73
function reduces even further this number. In DKO-MEFs,
despite the absence of p53, lack of p73 still hinders
reprogramming efficiency, suggesting that p73 performs a
required function that cannot be by-passed by elimination of
p53 stress–response barriers. Cell growth rate is a key
parameter controlling reprogramming.27 In this regard, reports
indicated that p73-deficient MEFs had decreased S phase and
Figure 7 Smad6 is a direct DNp73 transcriptional target. (a–c) P19 cells were transfected with either (a) TA-, DNp73 or vector control, or (b,c) Smad6-promoter reporter
system. After 18 h cells were serum-deprived for 24 h and then treated with BMP4. At the indicated time points samples were collected and analyzed. (a) Quantification of Smad6
expression level was analyzed by qRT-PCR. (b and c) Transcriptional analysis was performed with the reporter vector pGL2-mSmad6-promoter (-3123)-luc, a BMP-responsive
reporter construct that includes the p53-RE, together with the indicated expression vectors in the presence or absence of BMP4. (c) TAp73 (0.2 ug) was co-transfected with
increasing amounts of DNp73 (0.2–0.6 μg) before BMP4 treatment. Luciferase activity was normalized by the Renilla activity of the same lysate. Bars represent mean values± S.
E.M of at least four experiments; ns: not significant. (d) ChIP analysis of H1299 cells cultured in 10% serum conditions were performed using isotypic-antibody (rabbit IgG), anti-
HA or anti-DNp73 specific antibodies. Real-time PCR using specific primers to amplify p53-RE of the human or mouse Smad6 promoter, or p53-RE in the p21Cip1 promoter as
control, were performed and the data were normalized to input chromatin samples of each case and to IgG values= 1. Additional control was performed immunoprecipitating with
either rabbit IgG or anti-TAp73 and anti-DNp73 specific antibodies, and PCR amplifying the ChIP product with primers specific to a region at the vicinity of the identified p53-RE
(1700 bp downstream of the p53-RE), but without homology to this site (H1299 control). Experiments were repeated four times per duplicate. Bars represent mean values±S.E.
M; equal variance. Student's t-test was performed to evaluate statistical differences; *Po0.05, **Po0.01, ***Po0.001
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their long-term cell growth rate became different from WT-
cultures after 6 passages in culture,46 opening the possibility
that the observed effect was due to differences in the MEFs
proliferative index. However, in our hands, daily growth curves
from early passage MEFs littermates revealed no significant
differences between WT and p73KO growth kinetics. This
indicates that p73 deficiency did not affect proliferating kinetics
at these early passages, when the reprogramming was
performed, therefore allowing the comparison of the repro-
gramming kinetics betweenWT vs. p73KO or p53KO vs. DKO.
However, it is possible that, at latter passages, proliferating
rates differences will begin to arise in p73-deficient MEFs.46
Nevertheless, in agreement with previous reports,46 p53
elimination accelerates proliferation dynamics
(Supplementary Figure 1b, compare right column panels with
left), and p53-deficient MEFs had an accelerated reprogram-
ming kinetic respect to WT- and p73KO-MEFs.
Trp53 role in reprogramming is not limited to the regulation
of cell growth rate,13 but can also restrain the process by the
inhibition of the MET.21 The BMP-induced mesenchymal-to-
epithelial transition is required during the early steps of
reprogramming.6 Here, we demonstrated that lack of p73
results in an attenuated MET transition that could account for
the reduced reprogramming efficiency detected in p73-
deficient cultures. We propose, for the first time, a model in
which p73 is part of the BMP circuit, acting as a positive
modulator of the signaling cascade, required for the OSKM-
induced BMP signaling during the initiation phase of
reprogramming.
DNp73 was the predominant isoform induced during the
initiation stage of MEFs reprogramming. In agreement, we
demonstrate that DNp73 is an enhancer of BMP cascade
through direct transcriptional repression of the BMP signaling
inhibitor, Smad6. Thus, lack of DNp73 expression during the
initial steps of reprogramming would lead to increased levels
of Smad6, which in turn, will blunt OSKM-induced BMP
signaling. Consequently, MET induction would be impaired,
resulting in an attenuated epithelial phenotype (with reduced
Cdh1 and Epcam levels) and subsequent altered maturation
and stabilization phases.
BMP signaling fails to induce an epithelial phenotype in the
absence of OSKM,6 suggesting that BMP regulation of MET is
dependent on cell-intrinsic factors. Thus, it is tempting to
speculate that p73, in addition to its BMP-enhancing function,
could act as a pro-epithelial factor. This idea is supported by
the fact that p73-deficient iPSC colonies showed altered
morphology and attenuated epithelial phenotype. p73KO-
iPSCs displayed defective intercellular interactions with low
and diffuse expression of E-Cadherin as well as cytoplasmic
localization of β-catenin. These intercellular interactions are
crucial for colony compaction and full pluripotency
maintenance.34 Therefore, the altered morphology of the
p73-deficient colonies could reflect the link between pluripo-
tency and the requirement for certain intercellular interactions
that might be defective in the absence of p73. Supporting the
idea that p73-deficient cells might not be attaining full
stemness, it is noteworthy their low levels of Lin28, considered
necessary to obtain fully reprogrammed and stable iPSCs.32
Taken together, our data reveal that p73 is a positive
modulator of the BMP circuit, required for BMP-induced MET
during somatic cell reprogramming. Our findings provide
mechanistic insight into the MET regulation, supporting a
specific p73 function, independent of DNp73-dominant-
negative effect over p53, and highlighting the yin-yang role
of the p53 family members as regulators of the reprogramming
process.
Materials and Methods
Mice husbandry and animal breeding. Animal experiments were
conducted in agreement with European (Council Directive 2010/63/UE) and
Spanish regulations (RD 53/2013) on the protection of experimental animals. All the
protocols used within this study had the appropriate institutional committee approval.
Breeding and genotyping of wild-type mice (WT), Trp73 knockouts (p73KO), Trp53
knockouts (p53KO) and the double mutants Trp73− /− ; Trp53− /− (DKO) were
performed as described before.47
Generating the TAp73Δtd/Δtd mouse. The cre-loxP strategy was used to
generate the TAp73 conditional knockout reporter allele (TAp73fltd). Genomic p73
DNA from intron 1 to intron 3 was amplified from mouse genomic DNA (C57BL/6). A
neomycin resistance gene (neo) flanked by frt sites was inserted in intron 3. LoxP
sites were cloned into the endogenous locus 5′ to exon 2 and 3′ of the frt-flanked
neo cassette. tdTomato was cloned upstream of the 5′ loxP site and the synthetic
CAG promoter was cloned downstream of the 3′ loxP site. The modified p73 locus
was cloned into pL253.48 Mouse embryonic stem cells (G4) electroporated with the
targeting vector were analyzed by Southern blot analysis for proper targeting of the
TAp73 conditional knockout reporter allele. Resulting chimaeras were mated with
C57BL/6 albino females and genotyped as described below. Mice with germline
transmission of the targeted allele (TAp73fltd) were intercrossed to generate
homozygous mice (TAp73fltd/fltd). TAp73fltd/fltd mice were intercrossed with Zp3-Cre
(C57BL/6) transgenic mice.49 TAp73fltd/+; Zp3-Cre mice were intercrossed to
generate TAp73fltd/Δtd; Zp3-Cre mice, which were subsequently intercrossed to
generate TAp73Δtd /Δtd mice. All procedures were approved by the IACUC at
University of Texas M.D. Anderson Cancer Center.
Cell culture. Mouse Embryonic Fibroblasts (MEFs), P19 cells and H1299-
DNp73β cells were cultured in Dulbecco's modified Eagle's medium (DMEM)
supplemented with 10% fetal bovine serum (FBS) and 2 mM L-Glutamine. MEFs
were maintained on 0.1% gelatin-coated plates. The Rep-MEFs, which contain a
unique copy of the doxycycline inducible polycistronic cassette encoding the OSKM
factors, were derived from the in vivo reprogrammable mice i4F28 and were kindly
provided by Dr. Manuel Serrano (Institute for Research in Biomedicine, Barcelona,
Spain). The DNp73 null MEFs29 and non-published TAp73Δtd/Δtd were provided
by Dr. Elsa Flores (Moffitt Cancer Center, Florida, USA) and were reprogrammed
using a replication-defective and persistent Sendai virus (SeV) policistronic vector
encoding the OKSM genes, reported to efficiently reprogrammed MEFs.50
P19 mouse embryonal carcinoma cells were kindly provided by Dr. Han Li
(Spanish National Cancer Research Centre, Madrid, Spain). H1299-DNp73β cells
were a gift of by Dr Xinbin Chen (University of California, Davis, USA). These cells
stably express the DNp73β isoform under control of a tetracycline-inducible system
‘Tet-off”.38 Cells were cultured in the presence of tetracycline (2 μg/ml). When it was
required, to induce DNp73 expression, cells were cultured without tetracycline.
Mouse Embryonic Fibroblasts were isolated from 13.5 days postcoitum embryos of
the above-mentioned genotypes using standard procedures. For the analysis of cell
growth rates, early passage cells derived from littermates were seeded at a
concentration of 10 000 cells per cm2 (for daily counts) or 20 000 cells per cm2 (for
serial passages following a 3T3 protocol).
For experiments with P19 and H1299 cells involving BMP4 treatment, cells were
serum-deprived (0.2% FBS) for 24 h, before the treatment with 0.5 to 50 ng/ml human
BMP4 (Peprotech, Rocky Hill, NJ, USA) as indicated. Transfection of P19 cells was
performed using Lipofectamine™2000 Transfection Reagent (Invitrogen, Carlsbad,
CA, USA), following the manufacturer's instructions. Eighteen hours after
transfection, cells were serum-deprived as described and cells were treated with
5 ng/ml BMP4.
Reprogramming of mouse embryonic fibroblast cells and
culture of iPSCs. Mouse iPSCs were generated using the piggyBac (PB)
transposition system, as previously described.23 The PB transposon vectors were
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kindly provided by Dr Hämäläinen (Biomedicum Stem Cell Centre, Helsinki, Finland)
including: (a) PB-TET-OSKM-IRES-βgeo, for the expression of mouse Oct4, Sox2,
Klf4 and c-Myc (OSKM) from a doxycycline (Dox)-inducible polycistronic construct,
(b) PB-CAG-rtTA, encoding the reverse tetracycline transactivator (rtTA) and (c)
pCAG-PBase, the expression vector for the transposase. Two independent
reprogramming experiments were performed, each including at least three
biological replicates from the indicated genotypes (with the exception of p53KO-
MEFs, n= 2), with two independent transfections per replicate.
Early passage MEFs from the indicated genotypes (WT, p73KO, p53KO and DKO)
were transfected with the Neon electroporation device (ThermoFisher, MA, USA),
according to the manufacturers instruction. Briefly, 200 000 cells (up to passage 4)
were electroporated with 1 μg PB-TET-mOSKM or PB-TET-mOSK, 0.5 μg PB-rtTA
and 0.5 μg pCAG-PBase plasmid. Expression of the transgenes was induced the
following day by treatment with 1.5 μg/ml Doxycycline (Dox) in iPSC media (DMEM
supplemented with 15% FBS, 2 mM L-Glutamine, 1 mM sodium pyruvate, 1 mM
nonessential amino acids, 0.1 mM β-mercaptoethanol and 1000 U/ml leukemia
inhibitory factor, LIF). Colonies were manually picked and cultured on mouse
fibroblast-inactivated feeder cells in iPSC media without Dox. Alkaline phosphatase
(AP) staining was performed with Alkaline Phosphatase Detection Kit (Merck,
Darmstadt, Germany) according to the manufacturer’s instructions. Transgene
expression was confirmed in MEFS from the four genotypes by β-galactosidase
activity (genes encoding OSKM were linked to a lacZ reporter).
The Rep-MEFs can be reprogrammed in vitro upon addition of doxycycline.28 Early
passage Rep-MEFs-WT were seeded at 200 000 cells/well of 6-well plate. Next day,
Rep-MEFs were treated with Dox at 1μg/ml (in iPSC media) to activate the cassette
during the whole process. Colonies appear around day 5 after treatment and were
stained for AP activity at day-1628
TAp73 and DNp73-specific knockout MEFs29 were infected with the tetracistronic
SeV vector encoding OKSM factors at MOI of 3. Tetracistronic SeV was developed,
generated, concentrated and tittered as previously described.50,51 Briefly, two days
before SeV transduction, 50 000 cells were plated in 6-well plates. Then, cells were
transduced with SeV vectors during 2 h at RT. Fresh media was added and cells were
incubated at 37 °C o/n. Next day, 25 000 cells were harvested and plated onto MEF
irradiated feeder cells with human embryonic stem cell (ESC) medium/MEF
conditioned media supplemented with 8 ng/ml basic fibroblast growth factor (Miltenyi,
Bergisch Gladbach, Germany). After 3 days of transduction, the culture medium was
changed every other day until the analysis of reprogramming efficiency.
In vitro differentiation of iPSCs. Cells were harvested and embryoid
bodies (EBs) were prepared by the hanging drop procedure as previously
described.52 Briefly, 20 μl-cell suspension drops (30 000 cell/ml in iPSC medium
without LIF) were cultured for 4 days hanging from the lid of a Petri dish. EBs were
then flushed down with EB medium and kept in suspension in bacteriological dishes
for 3 additional days. Then, EBs were transferred to 0.1% gelatin-coated tissue
culture plates and media was changed every 2 days. After 15 days, cells were fixed
with 4% para-formaldehyde and used for further analysis.
Immunostaining. Immunofluorescence was performed as described.33 The
following primary antibodies and dilutions were used: rat anti-CD31 1 : 1000 (BD,
Franklin Lakes, NJ, USA), mouse anti-Tuj-1 1 : 1000 (Covance, Princeton, NJ,
USA), mouse anti-AFP 1 : 1000 (Inmunostep, Salamanca, Spain), rabbit anti-Nanog
1:1000 (Chemicon, Billerica, MA, USA), mouse anti-SSEA-1 (MC-480) 1 : 100
(Pierce, Waltham, MA, USA), rabbit anti-E-cadherin 1 : 60 (Cell Signaling, MA,
USA), mouse anti-E-cadherin 1:200 (Cell Signaling, Danvers, MA, USA), rabbit anti-
β-catenin 1 : 200 (BD). Secondary antibodies were: Alexa 647 goat anti-IgG rabbit
(Molecular Probes, Eugene, OR, USA), Alexa 488 goat anti-IgG mouse (Molecular
Probes), Alexa 568 donkey anti-IgG rat (Molecular Probes), Cy3 donkey anti-IgG
rabbit (Jackson Immunoresearch, West Grove, PA, USA) and FITC donkey anti-IgG
mouse (Jackson Immunoresearch). Images were obtained with NIKON Eclip-
seTE2000 and ZEISS LSM 800 confocal microscope.
RNA isolation and real-time qRT-PCR analysis. Total RNA from
cultured cells was isolated using TRI reagent solution (Ambion, TX, USA) and
purified with a Nucleospin RNA cleanup kit (Macherey-Nagel, Düren, Germany),
according to the manufacturer’s instructions. DNase treatment was performed
separately using RQ1 DNase (Promega, WI, USA) in the presence of Protector
RNase inhibitor (Roche, Basel, Switzerland). First strand cDNA was synthesized
using up to 2 μg of total RNA and the High Capacity RNA-to-cDNA kit (Applied
Biosystems, Carlsbad, CA, USA). Gene expression was analyzed by real-time qRT-
PCR in a StepOnePlus Real-Time PCR System (Applied Biosystems) using
FastStart Universal SYBR Green Master (ROX) (Roche). All protocols were
performed according to the manufacturer´s instructions. Primers sequences and
conditions were described before53 and are indicated in the Supplementary Table 1.
mRNA expression levels were calculated according to the formula: relative
expression of gene= 2^(Ct internal reference-Ct gene), using 18S mRNA
expression as internal reference.
Western blot analysis. Immunoblot was performed as previously described54
with the following primary antibodies: rabbit anti-pSmad1/5 (Ser463/465) 1:1000
(Cell Signaling), rabbit anti-HA (Y11) 1:1000 (Santa Cruz Biotechnology, TX, USA),
rabbit anti-actin (20–33) 1:10 000 (Sigma, MO, USA), followed by the appropriate
HRP-conjugated secondary antibodies (Pierce). The enhanced chemiluminiscence
was detected with Super Signal West-Pico Chemiluminiscent Substrate (Pierce).
Luciferase assay. A plasmid containing a fragment of the mouse Smad6
promoter, inserted into pGL2-Basic vector (-3231-Luc),37 was kindly provided by Dr.
Kato and Dr. Miyazono (University of Tsukuba, Japan). This reporter construct
contains the putative p53-RE identified in the mouse Smad6 promoter region. P19
cells were transfected with 0.125 μg of the -3123-luc-pGL2-basic, 0.0625 μg of
pRLNull renilla and 0.6 μg of either pcDNA3-HA-TAp73α, pcDNA3-HA-ΔNp73α or
pcDNA3 expression vectors, using Lipofectamine™2000 Transfection Reagent
(Invitrogen) following the manufacturer's protocol. For the co-transfection
experiments, P19 cells were co-transfected with a fixed amount of TAp73
(0.2 μg) and different amounts of DNp73 from 0.2 to 0.6 μg. Eighteen hours after
transfection, cells were serum-deprived for 24 h, followed by BMP4 treatment (5 ng/
ml) as described before. Luciferase activity was assayed using the Dual-Luciferase
Reporter System (Promega) in a Berthold's luminometer. Firefly luciferase values
were normalized to the corresponding Renilla luciferase levels.
Chromatin immunoprecipitation. ChIP analysis was carried out as
previously described.55 Briefly, 20x106 H1299 cells, WT-iPSC or p73KO-iPSC were
fixed with 1% formaldehyde for 10 min at room temperature. The reaction was
stopped by addition of 0.125 mM glycine for 10 min at room temperature and cells
were washed with PBS and lysed in 0.7% SDS lysis buffer. Cross-linked chromatin
was fragmented by sonication to an average size of 400 bp using a Bioruptor®
sonicator (Diagenode, Liege, Belgium). Chromatin was immunoprecipitated with the
following antibodies: anti-p73 N terminal (Abcam, Cambridge, UK) and anti-p73 Delta
N (38c674) (Abcam). Antibodies and cell lysates were incubated overnight at 4 °C
before the addition of protein G-coupled magnetic beads (Dynabeads, Invitrogen) for
4 h at 4 °C. Negative controls were prepared by incubating parallel samples with non-
immune rabbit IgG and anti-HA (Santa Cruz Biotechnology) antibodies.
The protein-DNA cross-links were reversed in elution buffer (1% SDS and 50 mM
Tris-HCl), followed by RNase treatment overnight at 65 °C. The eluted material was
incubated with proteinase K for 3 h at 45 °C, and the DNA was purified using the
QIAquick PCR purification kit (Qiagen, Hilden, Germany). Real-time qPCR was
performed using SYBR Green PCR kit (Bio-Rad, CA, USA) in a StepOnePlus Real-
Time PCR System (Applied Biosystems). The signals were normalized to the input
(non-immune rabbit IgG immunoprecipitation). Primers encompassing the p53-RE in
the human SMAD6 promoter were as follows: 5′-CACTTTGGGAGGCTAGGG and
5′-CCGCCAAGTAGCTGGAAC (amplicon, 150 bp). Primers encompassing the non-
specific binding site (control) in the human SMAD6 promoter were as follows:
5′-GGACCAATCCCGACTTTACA and 5′-TAGGTGAGGGATCACGCTTT (amplicon,
218 bp). Primers encompassing the p53-RE in the mouse SMAD6 promoter were as
follows: 5′-CAGGCAGGGAACTCTTTCAG and 5′-GTAGCTGGCAACCACCATTA
(amplicon, 152 bp).
Sequence analysis and statistical analyses. In silico prediction of
putative p53-response elements (p53-RE) within the human SMAD6 promoter was
performed with the p53FamTaG data base.40 Sequence alignments, either between
the identified p53-RE and the human SMAD6 gene (ENSG00000137834) or the
mouse Smad6 (ENSMUSG00000036867) gene, were carried out using the
‘Pairwise sequence alignment’ (EMBOSS Needle) software, available from the
European Bioinformatics Institute.
Statistical analyses were performed using the Student’s two-tailed t-test. Values
with Po0.05 were considered statistically significant (*Po0.05, **Po0.01,
***Po0.005). The mean± S.E.M. of each value is represented. Figure legends
include, when necessary, specific details regarding the number of replicates and
independent replicates.
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